Nasdaq:VCYT
VERACYTE, INC.
VERACYTE delivers next-gen liquid biopsy solutions for cancer detection and monitoring across the global oncology market.
Key Metrics
Investment Thesis
Bull Case
Investors may consider VCYT due to its dominant market position in the rapidly expanding liquid biopsy sector with a proven track record of revenue growth. The transition to profitability coupled with a robust cash balance provides flexibility for further R&D investments and potential M&A opportunities. Proprietary technology combined with strong payer relationships offers durable competitive moats against new entrants.
Bear Case
Caution is warranted given the company's history of accumulated deficits and the high volatility typical of diagnostic test markets dependent on regulatory approvals. Rising operating expenses, particularly in marketing and R&D, could erode margins if revenue growth slows or fails to keep pace with investments. Investors should also consider potential dilution from share-based compensation plans and the cyclicality of healthcare spending.
About VERACYTE, INC.
VERACYTE, INC. (VCYT) is a leading provider of next-generation liquid biopsy and genomic profiling tests that identify genetic biomarkers in blood to detect and monitor cancer. The company serves oncology centers and laboratories globally with its proprietary Veracyte platform, offering comprehensive companion diagnostics for key therapeutic areas including lung, breast, prostate, and gastrointestinal cancers.
Analysis
Management Discussion
The company demonstrated a strong turnaround in financial performance, shifting from losses in prior years to generating $66.4M in net profit for the latest period reported. Revenue grew steadily over the five-year track record, reaching $517.1M, while operating cash flow turned highly positive at $136.3M, indicating healthy conversion of earnings to cash. However, substantial non-cash adjustments and depreciation charges suggest a capital-intensive asset base that requires ongoing maintenance and strategic reinvestment.
Industry Overview
The global liquid biopsy market is experiencing rapid expansion driven by advances in genomic sequencing technology and increasing adoption for early cancer detection and treatment monitoring. Regulatory bodies are increasingly scrutinizing companion diagnostics, creating both opportunities for innovation and challenges for market consolidation. Key players compete on assay sensitivity, specificity, and the breadth of validated biomarkers across various cancer types.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $296.5M | $361.1M | $445.8M | $517.1M |
| Cost of Revenue | $0 | $0 | $147.6M | $154.6M |
| Gross Profit | $296.5M | $361.1M | $298.1M | $362.5M |
| Operating Expenses | $337.6M | $446.8M | $282.0M | $304.8M |
| Operating Income | $-41.1M | $-85.8M | $16.1M | $57.8M |
| R&D | $40.6M | $57.3M | $69.3M | $70.8M |
| G&A | $76.5M | $86.2M | $110.6M | $110.8M |
| Marketing | $97.6M | $101.5M | $95.4M | $100.2M |
| Stock-Based Comp | $26.7M | $33.1M | $36.2M | $43.6M |
| D&A | $25.9M | $27.2M | $23.5M | $21.4M |
| Depreciation | $4.6M | $6.6M | $8.6M | $8.3M |
| Amortization | $21.4M | $20.6M | $14.8M | $13.2M |
| Other OpEx | $122.9M | $201.8M | $6.7M | $23.0M |
| Non-Operating Income | $4.7M | $9.2M | $9.6M | $10.4M |
| Pre-Tax Income | $-36.4M | $-76.6M | $25.7M | $68.2M |
| Income Tax | $133.0K | $-2.2M | $1.6M | $1.8M |
| Continuing Ops | $-36.6M | $-74.4M | $24.1M | $66.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-36.6M | $-74.4M | $24.1M | $66.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-36.6M | $-74.4M | $24.1M | $66.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $248.6M | $285.6M | $372.3M | $488.4M |
| Cash & Equivalents | $154.2M | $216.5M | $239.1M | $362.6M |
| Accounts Receivable | $44.0M | $40.4M | $46.5M | $44.7M |
| Inventory | $14.3M | $16.1M | $21.8M | $20.5M |
| Prepaid Expenses | $11.5M | $12.7M | $14.6M | $10.3M |
| Other Current Assets | $24.6M | $0 | $50.4M | $50.3M |
| Long-Term Assets | $907.8M | $829.3M | $927.8M | $917.6M |
| PP&E (Net) | $17.7M | — | — | — |
| Intangibles | $174.9M | $88.6M | $102.3M | $89.1M |
| Goodwill | $695.9M | $703.0M | $745.8M | $767.2M |
| Operating Leases | $13.2M | $10.3M | $48.2M | $36.6M |
| Other LT Assets | $6.2M | $27.4M | $31.5M | $24.7M |
| Total Assets | $1.16B | $1.11B | $1.30B | $1.41B |
| Current Liabilities | $62.6M | $61.2M | $78.6M | $59.9M |
| Accounts Payable | $11.9M | $12.9M | $8.6M | $4.6M |
| Current Debt | $0 | — | — | — |
| Current Leases | $4.1M | $5.1M | $7.5M | $4.1M |
| Deferred Revenue | $2.6M | $2.0M | $1.7M | $1.2M |
| Other Current Liab | $6.2M | $2.8M | $17.0M | $1.3M |
| Long-Term Liabilities | $18.6M | $9.6M | $45.4M | $36.5M |
| LT Operating Leases | $10.6M | $7.5M | $43.2M | $35.6M |
| Other LT Liab | $8.0M | $2.0M | $2.2M | $903.0K |
| Total Liabilities | $81.2M | $70.8M | $124.1M | $96.4M |
| Shareholders' Equity | $1.08B | $1.04B | $1.18B | $1.31B |
| Retained Earnings | $-393.7M | $-468.1M | $-444.0M | $-377.6M |
| AOCI | $-31.3M | $-24.0M | $-36.1M | $-8.2M |
| Total L&E | $1.16B | $1.11B | $1.30B | $1.41B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-36.6M | $-74.4M | $24.1M | $66.4M |
| Non-Cash Adjustments | $38.2M | $124.1M | $45.5M | $68.4M |
| Working Capital Changes | $5.9M | $-5.4M | $5.4M | $1.6M |
| Cash from Operations | $7.5M | $44.2M | $75.1M | $136.3M |
| Capital Expenditures | $8.5M | $10.0M | $11.3M | $9.7M |
| Cash from Investing | $-29.4M | $15.1M | $-56.3M | $-9.2M |
| Debt Repayments | $1.3M | $0 | $0 | — |
| Cash from Financing | $3.5M | $2.8M | $4.9M | $-4.2M |
| FX Effect | $-592.0K | $163.0K | $-424.0K | $719.0K |
| Net Change in Cash | $-18.9M | $62.3M | $23.3M | $123.6M |
| Beginning Cash | $173.9M | $155.0M | $217.3M | $240.6M |
| Ending Cash | $155.0M | $217.3M | $240.6M | $364.2M |
Frequently Asked Questions
How does VERACYTE, INC. make money?
Revenue is primarily derived from diagnostic test sales to clinical laboratories and academic research institutions. The company's portfolio includes VeriSeq and Verigene platforms, which are used for companion diagnostics in lung cancer (NSCLC), breast cancer, prostate cancer, and colorectal cancer monitoring. Significant portions of operating expenses are allocated to Research and Development and General & Administrative functions supporting global expansion.
What are the main risks for VCYT?
Regulatory risks related to potential changes in FDA or CMS reimbursement policies could impact the demand for liquid biopsy tests. Intense competition from emerging biotech firms entering the liquid biopsy space may pressure market share and pricing margins. The company's significant accumulated deficit and reliance on cash flow generation necessitate careful monitoring of burn rates relative to growth investments.
What is VCYT's competitive advantage?
VERACYTE possesses a robust proprietary technology platform with deep intellectual property protection in liquid biopsy methodologies. The company has secured extensive regulatory approvals and payer coverage for its companion diagnostics, creating high barriers to entry against competitors. Strong partnerships with major pharmaceutical companies and academic institutions provide a sustainable revenue pipeline and clinical validation.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.